Strategies and validation for siRNA-based therapeutics for the reversal of multi-drug resistance in cancer

Drug Discovery Today

Volumn 19, Issue 1, 2014, Pages 71-78

  Fatemian, Tahereh ^a   Othman, Iekhsan ^a   Chowdhury, Ezharul Hoque ^a  

^a MONASH UNIVERSITY MALAYSIA   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AURORA KINASE; MICRORNA; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN P53; SMALL INTERFERING RNA; SURVIVIN;

CANCER CELL; CANCER THERAPY; DRUG EFFICACY; GENE IDENTIFICATION; GENE SILENCING; GENE TARGETING; HUMAN; MULTIDRUG RESISTANCE; NEOPLASM; PROTEIN TARGETING; REVIEW; RNA INTERFERENCE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; REPRODUCIBILITY OF RESULTS; RNA, SMALL INTERFERING;

EID: 84891838243     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2013.08.007     Document Type: Review

References (62)

1. S. Grivennikov Immunity, inflammation, and cancer Cell 140 2010 883 899
2. Z.H. Siddik et al. Drug Resistance in Cancer Cells 2009 Springer
3. T. Ozben Mechanisms and strategies to overcome multiple drug resistance in cancer FEBS Lett. 580 2006 2903 2909
4. V. Fodale et al. Mechanism of cell adaptation: when and how do cancer cells develop chemoresistance? Cancer J. 17 2011 89 95
5. B. Györffy et al. Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations Int. J. Cancer 118 2006 1699 1712
6. G. Szakács et al. Multidrug resistance mediated by MDR-ABC transporters Z.H. Siddik, K. Mehta, Drug Resistance in Cancer Cells 2009 Springer 1 20
7. T. Yokoyama et al. The role of autophagy and apoptosis in the drug resistance of cancer Z.H. Siddik, K. Mehta, Drug Resistance in Cancer Cells 2009 Springer 53 71
8. Y. Guo MRP8, ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2′,3′- dideoxycytidine and 9′-(2′-phosphonylmethoxyethyl)adenine J. Biol. Chem. 278 2003 29509 29514
9. Z.S. Chen Transport of bile acids, sulfated steroids, estradiol 17-beta-d-glucuronide, and leukotriene C4 by human multidrug resistance protein 8 (ABCC11) Mol. Pharmacol. 67 2005 545 557
10. E. Hopper-Borge Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel Cancer Res. 64 2004 4927 4930
11. E. Hopper-Borge Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epothilone B Cancer Res. 69 2009 178 184
12. H.M. Aliabadi et al. Effective down-regulation of breast cancer resistance protein (BCRP) by siRNA delivery using lipid-substituted aliphatic polymers Eur. J. Pharm. Biopharm. 81 2012 33 42
13. P.S. Hodkinson, and T. Sethi Extracellular matrix-mediated drug resistance Z.H. Siddik, K. Mehta, Drug Resistance in Cancer Cells 2009 Springer 115 135
14. Z.H. Siddik Drug resistance and the tumor suppressor p53: the paradox of wild-type genotype in chemorefractory cancers Z.H. Siddik, K. Mehta, Drug Resistance in Cancer Cells 2009 Springer 209 231
15. J.E. Wilcox DNA repair by ERCC1 in non-small-cell lung cancer N. Engl. J. Med. 355 2006 2590 2591
16. B. Al-Lazikani et al. Combinatorial drug therapy for cancer in the post-genomic era Nat. Biotechnol. 30 2012 679 692
17. T. Christoffersen et al. Cancer therapy targeted at cellular signal transduction mechanisms: strategies, clinical results, and unresolved issues Eur. J. Pharmacol. 625 2009 6 22
18. A. Zelnak Overcoming taxane and anthracycline resistance Breast J. 16 2010 309 312
19. S. Palakurthi et al. Recent trends in cancer drug resistance reversal strategies using nanoparticles Expert Opin. Drug Deliv. 9 2012 287 301
20. Y.T. Li et al. Reversing multidrug resistance in breast cancer cells by silencing ABC transporter genes with nanoparticle-facilitated delivery of target siRNAs Int. J. Nanomed. 7 2012 2473 2781
21. C.H. Choi ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal Cancer Cell Int. 5 2005 30
22. J. Guo et al. Can non-viral technologies knockdown the barriers to siRNA delivery and achieve the next generation of cancer therapeutics? Biotechnol. Adv. 29 2011 402 417
23. K.H. Kelly et al. Gene Therapy for Cancer 2009 Humana Press Inc
24. G.R. Devi siRNA-based approaches in cancer therapy Cancer Gene Ther. 13 2006 819 829
25. Z. Wang et al. RNA interference and cancer therapy Pharm. Res. 28 2011 2983 2995
26. E.H. Chowdhury Strategies for tumor-directed delivery of siRNA Expert Opin. Drug Deliv. 8 2011 389 401
27. B. Bonavida Sensitization of Cancer Cells for Chemo/immuno/radio-therapy 2008 Springer
28. A. Stege et al. Overcoming multidrug resistance by RNA interference Methods Mol. Biol. 596 2010 447 465
29. M.E. Davis et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles Nature 464 2010 1067 1070
30. F. Petrocca et al. Promise and challenge of RNA interference-based therapy for cancer J. Clin. Oncol. 29 2011 747 754
31. C. Phalon et al. Potential use of RNA interference in cancer therapy Expert Rev. Mol. Med. 12 2010 E26
32. O. Patutina et al. The siRNA targeted to mdr1b and mdr1a mRNAs in vivo sensitizes murine lymphosarcoma to chemotherapy BMC Cancer 10 2010 204
33. Y. Donmez et al. Reversal of multidrug resistance by small interfering RNA (siRNA) in doxorubicin-resistant MCF-7 breast cancer cells Biomed. Pharmacother. 65 2011 85 89
34. J. Jiang et al. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin Eur. J Pharm. Biopharm. 76 2010 170 178
35. J. Hua et al. Stable suppression of MDR-1 gene using siRNA expression vector to reverse drug resistance in a human uterine sarcoma cell line Gynecol. Oncol. 98 2005 31 38
36. J.M. Li et al. Multifunctional QD-based co-delivery of siRNA and doxorubicin to HeLa cells for reversal of multidrug resistance and real-time tracking Biomaterials 33 2012 2780 2790
37. C. Liu et al. Novel biodegradable lipid nano complex for siRNA delivery significantly improving the chemosensitivity of human colon cancer stem cells to paclitaxel J. Control. Release 140 2009 277 283
38. Z. Wu et al. In vitro and in vivo inhibition of MRP gene expression and reversal of multidrug resistance by siRNA Basic Clin. Pharmacol. Toxicol. 108 2011 177 184
39. M. Saad et al. Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer Nanomedicine (Lond.) 3 2008 761 776
40. C. Quezada et al. 5′-Ectonucleotidase mediates multiple-drug resistance in glioblastoma multiforme cells J. Cell Physiol. 228 2013 602 608
41. T. Uemura et al. ABCC11/MRP8 confers pemetrexed resistance in lung cancer Cancer Sci. 101 2010 2404 2410
42. H. You et al. Small interfering RNA targeting the subunit ATP6L of proton pump V-ATPase overcomes chemoresistance of breast cancer cells Cancer Lett. 280 2009 110 119
43. H. Yanagie et al. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro Biomed. Pharmacother. 63 2009 553 560
44. Y.H. Kuang et al. RNA interference targeting the CD147 induces apoptosis of multi-drug resistant cancer cells related to XIAP depletion Cancer Lett. 276 2009 189 195
45. J.L. Liu et al. Inhibition of survivin expression and mechanisms of reversing drug-resistance of human lung adenocarcinoma cells by siRNA Chin. Med. J. (Engl.) 123 2010 2901 2907
46. H. Yang et al. Influence of SiRNA targeting survivin on chemosensitivity of H460/cDDP lung cancer cells J. Int. Med. Res. 36 2008 734 747
47. W.S. Liu et al. siRNA directed against survivin enhances pancreatic cancer cell gemcitabine chemosensitivity Dig. Dis. Sci. 54 2009 89 96
48. S. Fuessel et al. Chemosensitization of bladder cancer cells by survivin-directed antisense oligodeoxynucleotides and siRNA Cancer Lett. 232 2006 243 254
49. H.Y. Xue, and H.L. Wong Tailoring nanostructured solid-lipid carriers for time-controlled intracellular siRNA kinetics to sustain RNAi-mediated chemosensitization Biomaterials 32 2011 2662 2672
50. K. Nakao et al. Survivin downregulation by siRNA sensitizes human hepatoma cells to TRAIL-induced apoptosis Oncol. Rep. 16 2006 389 392
51. S.S. Singhal et al. Depletion of RLIP76 sensitizes lung cancer cells to doxorubicin Biochem. Pharmacol. 70 2005 481 488
52. S.S. Singhal et al. Regression of prostate cancer xenografts by RLIP76 depletion Biochem. Pharmacol. 77 2009 1074 1083
53. L. Xie et al. Kinome-wide siRNA screening identifies molecular targets mediating the sensitivity of pancreatic cancer cells to Aurora kinase inhibitors Biochem. Pharmacol. 83 2012 452 461
54. J.C. Pang et al. KIAA0495/PDAM is frequently downregulated in oligodendroglial tumors and its knockdown by siRNA induces cisplatin resistance in glioma cells Brain Pathol. 20 2010 1021 1032
55. J. Niu et al. siRNA-mediated type 1 insulin-like growth factor receptor silencing induces chemosensitization of a human liver cancer cell line with mutant P53 Cell Biol. Int. 31 2007 156 164
56. Y.P. Park et al. Human telomerase reverse transcriptase (hTERT): a target molecule for the treatment of cisplatin-resistant tumors Korean J. Lab. Med. 28 2008 430 437
57. X. Dong et al. siRNA inhibition of telomerase enhances the anti-cancer effect of doxorubicin in breast cancer cells BMC Cancer 9 2009 133
58. S. Su et al. SiRNA inhibition of GRP58 associated with decrease in mitomycin C-induced DNA cross-linking and cytotoxicity Chem. Biol. Interact. 162 2006 81 87
59. F.Y. Hsu et al. Downregulation of NPM-ALK by siRNA causes anaplastic large cell lymphoma cell growth inhibition and augments the anti cancer effects of chemotherapy in vitro Cancer Invest. 25 2007 240 248
60. C.J. Dougherty et al. Selective apoptosis of breast cancer cells by siRNA targeting of BORIS Biochem. Biophys. Res. Commun. 370 2008 109 112
61. Y.W. Zhang et al. Implication of checkpoint kinase-dependent up-regulation of ribonucleotide reductase R2 in DNA damage response J. Biol. Chem. 284 2009 18085 18095
62. H.N. He Concurrent blockade of the NF-kappa B and Akt pathways potently sensitizes cancer cells to chemotherapeutic-induced cytotoxicity Cancer Lett. 295 2010 38 43